Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors.

ABSTRACT: SYNTHETIC CANCER VACCINES: A number of fully synthetic vaccine candidates have been designed, chemically synthesized, and immunologically evaluated to establish a strategy to overcome the poor immunogenicity of tumor-associated carbohydrates and glycopeptides and to determine the importance of Toll-like receptor (TLR) engagement for antigenic responses against these compounds.Epithelial cancer cells often overexpress mucins that are aberrantly glycosylated. Although it has been realized that these compounds offer exciting opportunities for the development of immunotherapy for cancer, their use is hampered by the low antigenicity of classical immunogens composed of a glycopeptide derived from a mucin conjugated to a foreign carrier protein. We have designed, chemically synthesized, and immu

SUBMITTER: Ingale S 

PROVIDER: S-EPMC2806797 | biostudies-literature | 2009 Feb

REPOSITORIES: biostudies-literature